$CRSP

CRISPR Therapeutics AG

CIK:0001674416|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenue	$ 10,181	$ 892	$ 11,639	$ 1,757
Operating expenses:
Research and development	67,152	69,894	135,726	142,378
Acquired in-process research and development	2,473	96,253	2,473	96,253
General and administrative	17,553	18,916	34,736	38,212
Collaboration expense, net	40,272	45,153	86,221	102,662
Total operating expenses	127,450	230,216	259,156	379,505
Loss from operations	(117,269)	(229,324)	(247,517)	(377,748)
Other income:
Other income, net	27,075	22,067	35,231	35,604
Total other income, net	27,075	22,067	35,231	35,604
Net loss before income taxes	(90,194)	(207,257)	(212,286)	(342,144)
Provision for income taxes	(960)	(1,292)	(1,799)	(2,401)
Net loss	(91,154)	(208,549)	(214,085)	(344,545)
Foreign currency translation adjustment	6	80	(26)	121
Unrealized (loss) gain on marketable securities	(2,694)	(174)	(9,424)	2,080
Comprehensive loss	$ (93,842)	$ (208,643)	$ (223,535)	$ (342,344)
Net loss per common share - basic	$ (0.94)	$ (2.4)	$ (2.22)	$ (3.98)
Basic weighted-average common shares outstanding	96,514,102	87,069,690	96,283,944	86,507,330
Net loss per common share - diluted	$ (0.94)	$ (2.4)	$ (2.22)	$ (3.98)
Diluted weighted-average common shares outstanding	96,514,102	87,069,690	96,283,944	86,507,330
Collaboration Revenue [Member]
Revenue:
Total revenue	$ 10,000	$ 0	$ 11,000	$ 0
Grant Revenue [Member]
Revenue:
Total revenue	$ 181	$ 892	$ 639	$ 1,757

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net loss	$ (214,085)	$ (344,545)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	8,599	9,385
Equity-based compensation	33,640	37,819
Other non-cash items, net	(4,763)	(5,075)
Amortization of debt issuance costs	848	0
Acquired in-process research and development	2,473	96,253
Changes in:
Accounts receivable	0	25,000
Prepaid expenses and other assets	(1,088)	(727)
Accounts payable and accrued expenses	(18,321)	28,298
Deferred revenue	(582)	(1,716)
Operating lease assets and liabilities	(3,064)	(2,421)
Other liabilities, net	3,948	(10,098)
Net cash used in operating activities	(192,395)	(167,827)
Investing activities:
Purchases of property, plant and equipment	(1,152)	(323)
Investment in equity securities	(13,343)	(9,700)
Purchases of in-process research and development	(2,473)	(25,000)
Purchases of marketable securities	(952,388)	(411,111)
Maturities of marketable securities	184,253	397,147
Sales of marketable securities	318,701	99,209
Net cash (used in) provided by investing activities	(466,402)	50,222
Financing activities:
Proceeds from issuance of the Notes	600,000	0
Issuance costs and discounts associated with the Notes	(14,650)	0
(Payments) proceeds from issuance of common shares, net of issuance costs	(722)	8,494
Proceeds from exercise of options and ESPP contributions, net of issuance costs	14,460	4,352
Net cash provided by financing activities	599,088	12,846
Effect of exchange rate changes on cash	(26)	121
Decrease in cash	(59,735)	(104,638)
Cash, cash equivalents and restricted cash, beginning of period	359,078	309,776
Cash, cash equivalents and restricted cash, end of period	299,343	205,138
Supplemental disclosure of non-cash investing and financing activities
Equity issuance costs in accounts payable, accrued expenses, and other long-term liabilities	3,935	3,899
Acquired in-process research and development expense related to issuance of common shares	$ 0	$ 71,253

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 291,337	$ 347,559
Marketable securities	2,073,015	1,628,269
Prepaid expenses and other current assets	7,418	9,843
Total current assets	2,371,770	1,985,671
Property and equipment, net	108,068	115,851
Restricted cash	7,629	7,629
Operating lease assets	125,592	131,724
Other non-current assets	37,711	24,368
Total assets	2,650,770	2,265,243
Current liabilities:
Accounts payable	11,307	11,138
Accrued expenses	70,278	89,407
Deferred revenue, current	15,189	15,771
Accrued tax liabilities	494	1,113
Operating lease liabilities	18,646	18,578
Other current liabilities	16,982	13,113
Total current liabilities	132,896	149,120
Long-term debt	586,198	0
Operating lease liabilities, net of current portion	178,904	188,168
Other non-current liabilities	6,221	6,142
Total liabilities	904,219	343,430
Commitments and contingencies, see Note 7
Shareholders’ equity:
Common shares, CHF 0.03 nominal value, 144,447,967 and 132,477,166 shares authorized at June 30, 2026 and December 31, 2025, respectively, 96,761,275 and 96,009,657 shares issued at June 30, 2026 and December 31, 2025, respectively, 96,660,959 and 95,894,341 shares outstanding at June 30, 2026 and December 31, 2025, respectively	3,130	3,087
Treasury shares, at cost, 100,316 and 115,316 shares at June 30, 2026 and December 31, 2025, respectively.	(60)	(60)
Additional paid-in capital	3,909,746	3,861,516
Accumulated deficit	(2,161,636)	(1,947,551)
Accumulated other comprehensive (loss) income	(4,629)	4,821
Total shareholders' equity	1,746,551	1,921,813
Total liabilities and shareholders’ equity	$ 2,650,770	$ 2,265,243